Cure8 research brief
Microbial metabolites that activate GPCRs could influence gut hormones and immune signaling linked to IBD risk. Understanding these pathways may point to new biomarkers or targets for future therapies.
Researchers studying microbiome–host interactions, clinicians and scientists interested in IBD pathogenesis or GPR35, and informed patients curious about microbiome mechanisms.
The authors screened libraries of gut metabolites using a multiplexed GPCR reporter (GPCR-seq) to identify intestinal chemosensory pathways. They report that a cyclic fatty acid stimulates serotonin release from enterochromaffin cells via olfactory receptor OR51E1. They also identify a β-carboline and 6-HNA as GPR35 agonists.
Importantly, an IBD-associated GPR35 variant (T108M) shows altered responses to 6-HNA, and Enterocloster bolteae — a species reported as increased in IBD — produces high levels of 6-HNA.
The paper is an early, mechanistic, basic-science investigation: it maps receptor–ligand interactions and links them to genetic variants and microbial producers, but it does not test clinical interventions or patient outcomes. The abstract is the source for this brief summary.
This classification and note are based on the article abstract (Cell Host & Microbe). The study reports molecular and mechanistic findings; it does not provide clinical trial results or demonstrate therapeutic benefit. As an abstract-based summary, it does not replace reading the full paper.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of interests R.J.X. is a scientific advisory board member at Nestlé and Magnet BioMedicine and a board director at MoonLake Immunotherapeutics; these organizations had no roles in this study.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers found that immune cells detect the gut-associated yeast Debaryomyces hansenii via Dectin-1 and Card9, and the yeast was enriched in Crohn’s disease ulcers. That suggests a possible microbial–immune link...
Identifies a molecule (CCL3) linked to more severe inflammation in IBD tissues, which could help researchers develop new biomarkers or treatments targeting immune-cell recruitment and polarization.
Purinergic signaling connects nerves, immune cells, epithelium, and microbiota in the gut — pathways that can influence inflammation, motility, and pain relevant to IBD. Understanding these mechanisms could point to new...
